Achieve Life Sciences, Inc. (ACHV)
| Market Cap | 618.01M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -51.99M |
| Shares Out | 102.66M |
| EPS (ttm) | -1.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,441,203 |
| Open | 5.73 |
| Previous Close | 5.70 |
| Day's Range | 5.68 - 6.06 |
| 52-Week Range | 2.00 - 6.16 |
| Beta | 2.26 |
| Analysts | Strong Buy |
| Price Target | 13.11 (+117.77%) |
| Earnings Date | Aug 6, 2026 |
About ACHV
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ACHV stock is "Strong Buy." The 12-month stock price target is $13.11, which is an increase of 117.77% from the latest price.
News
Achieve Life Sciences resumed with a Strong Buy at Raymond James
Raymond James resumed coverage of Achieve Life Sciences (ACHV) with a Strong Buy rating and $20 price target Achieve’s cytisinicline, supported by Phase 2b and Phase 3 ORCA data, is…
Achieve Life Sciences CRL from FDA cites deficiencies at manufacturing facility
Achieve Life Sciences (ACHV) announced that it has received a complete response letter, or CRL, from the FDA regarding the new drug application, or NDA, for cytisinicline. The CRL relates…
US FDA declines to approve Achieve Life Sciences' smoking-cessation drug
The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat nicotine dependence in adults, the company said on Monday.
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA
CRL Cites Deficiencies at Third-Party Manufacturing Facility No Efficacy or Clinical Safety Deficiencies Identified SEATTLE and VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) -- Achieve L...
Achieve Life Sciences Proxy statement: Proxy filing
Achieve Life Sciences filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
Appointments Add Deep Biopharmaceutical Commercial Strategy, Clinical and Finance Expertise as Company Advances Toward Potential Cytisinicline Approval and Launch Appointments Add Deep Biopharmaceutic...
Achieve Life Sciences Proxy statement: Proxy filing
Achieve Life Sciences filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52 week...
Achieve Life Sciences files prospectus for resale of shares by holders
Achieve Life Sciences (ACHV) filed a prospectus relating to the resale by selling shareholders, from time to time, of up to 49.42M shares of common stock.
Achieve Life Sciences Earnings Call Transcript: Q1 2026
Strong capital raise and new leadership position the company for NDA resubmission in Q4 2026 and a first-half 2027 commercial launch, with U.S.-based manufacturing and robust clinical data supporting cytisinicline’s potential as a first-in-class therapy for smoking and vaping cessation.
Achieve Life Sciences Earnings release: Q1 2026
Achieve Life Sciences released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Achieve Life Sciences Quarterly report: Q1 2026
Achieve Life Sciences has published its Q1 2026 quarterly earnings report on May 12, 2026.
Achieve Life Sciences Registration statement: Registration filing
Achieve Life Sciences filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Achieve Life Sciences reports Q1 EPS (19c), consensus (30c)
“Achieve is a mission-driven company. Nicotine dependence is one of the largest preventable public health hazards we know, and smoking remains the leading cause of preventable death,” said Andrew D.
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma
Christopher Martin joins the Board of Directors, with Mark Zappia and Jim Willis joining as Senior Vice President of Commercial and Vice President of Sales, reuniting the team behind the launch of Oht...
Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates
Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants Appoints New CEO and Expands Board of Directors Advances U . S . -based Man...
Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026
SEATTLE and VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development an...
Achieve Life Sciences Slides: Corporate presentation
Achieve Life Sciences has posted slides in relation to its latest quarterly earnings report, which was published on May 1, 2026.
Achieve Life Sciences initiated with a Buy at Canaccord
Canaccord analyst Gary Nachman last night initiated coverage of Achieve Life Sciences (ACHV) with a Buy rating and $13 price target The company’s cytisinicline is a “best-in-class” drug for nicotine…
Achieve Life Sciences initiated with a Buy at Canaccord
Canaccord initiated coverage of Achieve Life Sciences (ACHV) with a Buy rating and $13 price target
Achieve Life Sciences announces $354M private placement
Before the market opened, Achieve Life Sciences (ACHV) announced it had entered into a securities purchase agreement with healthcare investors for a private placement of its securities for gross proce...
Achieve Life Sciences appoints Goldberg as CEO, names two leaders to board
Achieve Life Sciences (ACHV) announced it has appointed Andrew Goldberg, MD, as Chief Executive Officer and as a member of the Board of Directors, effective following the closing of Achieve’s…
Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors
Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Miles...
Achieve Life Sciences Announces Up to $354 Million Private Placement
$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval
Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions
Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing Capability Company Reiterates Guidance - If Approved, Cytisinicline Commercial Launch Expected in First Half of 2027 SEA...